Team

Our mission is to provide groundbreaking therapies to patients suffering from disease.

CEO&Co-Founder　Ph.D　中井 貴士／Nakai Takashi
After earning a master’s degree at Kyoto University’s Graduate School of Engineering, he conducted antibody and DDS research at Chugai Pharmaceutical. While at Tokyo Medical and Dental University, he invented hyaluronic acid nanogel (Sonanos™) and earned a Ph.D. He later joined Asahi Kasei to commercialize the nanogel and led clinical trials for a cancer vaccine in collaboration with Mie University.

COO&Co-Founder　黒澤 丈朗 ／KUROSAWA TAKERO

After a master’s degree from National Taiwan University,  University of Bordeaux, and the Graduate School of Agro-Biomedical Science at University of Tsukuba, joined to BluePass Capital as an analyst. Later, provided strategic consulting services for enhancing corporate value to private equity (PE) fund portfolio companies at Prored Partners. Subsequently, at Asahi Kasei Corporation, managed the global reaching of Sonanos™ as a business development, playing a variety of role in launching DRG.

Scientific Advisor　Ph.D, MD　宮原 慶裕/Yoshihiro Miyahara 
After graduating from the Faculty of Medicine at Mie University, Dr. Miyahara joined the Second Department of Internal Medicine. He earned his doctoral degree and subsequently studied at Baylor College of Medicine in Houston, Texas, and at the University of Toledo in Ohio. Upon returning to Japan, he became a lecturer in the Cancer Vaccine Department at Mie University’s Graduate School of Medicine. In May 2016, he was appointed Associate Professor at the Division of Gene and Immune Cell Therapy, and in March 2018, he became Professor of the Division of Personalized Cancer Immunotherapy.

Company Overview

Company Name  　DiveRadGel 株式会社

English version   　DiveRadGel Co., Ltd.

Representative　　CEO:Takashi Nakai

Headquarters　　　Ginza, Chuo-ku, Tokyo

Establishment　　　June 10, 2024

Capital　　　　　　  2 million yen

Fiscal Year End　　 May